(E)-AG 556

CAS No. 133550-41-1

(E)-AG 556( (E)-Tyrphostin AG 556 )

Catalog No. M27474 CAS No. 133550-41-1

AG 556 is a selective inhibitor of EGFR and blocks LPS-induced TNF-α production.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
10MG 29 In Stock
25MG 56 In Stock
50MG 85 In Stock
100MG 136 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    (E)-AG 556
  • Note
    Research use only, not for human use.
  • Brief Description
    AG 556 is a selective inhibitor of EGFR and blocks LPS-induced TNF-α production.
  • Description
    AG 556 is a selective inhibitor of EGFR and blocks LPS-induced TNF-α production.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    (E)-Tyrphostin AG 556
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    133550-41-1
  • Formula Weight
    336.38
  • Molecular Formula
    C20H20N2O3
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (297.28 mM)
  • SMILES
    N#C/C(/C(NCCCCc1ccccc1)=O)=C\c(cc1)cc(O)c1O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Qa'dan F, et al. Cinchonain Ib isolated from Eriobotrya japonica induces insulin secretion in vitro and in vivo. J Ethnopharmacol. 2009 Jul 15;124(2):224-7.
molnova catalog
related products
  • HER2/neu (654-662) G...

    Affibody (affibody) ligands that are specific for the extracellular domain of human epidermal growth factor receptor 2 (HER2/neu) have been selected by phage display technology from a combinatorial protein library based on the 58 amino acid residue staphylococcal protein A-derived Z domain.

  • ICA-105574

    ICA-105574 is an activator of hERG that binds to the channel to remove inactivation, thus increasing peak current amplitude and shortening the action potential. It also modulates activation kinetics of the channel.

  • Vandetanib

    Vandetanib is an orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGFR2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability.